HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer's disease

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Fujita, Kyota ^a   Motoki, Kazumi ^a   Tagawa, Kazuhiko ^a   Chen, Xigui ^a   Hama, Hiroshi ^b   Nakajima, Kazuyuki ^c   Homma, Hidenori ^a   Tamura, Takuya ^a   Watanabe, Hirohisa ^d   Katsuno, Masahisa ^d   Matsumi, Chiemi ^e   Kajikawa, Masunori ^e   Saito, Takashi ^b   Saido, Takaomi ^b   Sobue, Gen ^d   Miyawaki, Atsushi ^b   Okazawa, Hitoshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^c SOKA UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Medical & Biological Laboratories Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; MARCKS PROTEIN; MARCKS PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; SERINE; TAU PROTEIN; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4;

ALZHEIMER DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; NEURITE; PATHOLOGY; PHOSPHORYLATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; HMGB1 PROTEIN; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; MYRISTOYLATED ALANINE-RICH C KINASE SUBSTRATE; NEURITES; PHOSPHORYLATION; SERINE; TAU PROTEINS; TOLL-LIKE RECEPTOR 4;

EID: 84984698433     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31895     Document Type: Article

References (61)

1. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics. Science 297, 353-356, doi: 10.1126/science.1072994 (2002)
2. Doody, R. S. et al. A phase 3 trial of semagacestat for treatment of Alzheimers disease. N Engl J Med 369, 341-350, doi: 10.1056/ NEJMoa1210951 (2013)
3. Doody, R. S., Farlow, M., Aisen, P. S., Committee, A. s. D. C. S. D. A. & Publication. Phase 3 trials of solanezumab and bapineuzumab for Alzheimers disease. N Engl J Med 370, 1460, doi: 10.1056/NEJMc1402193 (2014)
4. Selkoe, D. J. Resolving controversies on the path to Alzheimers therapeutics. Nat Med 17, 1060-1065, doi: 10.1038/nm.2460 (2011)
5. Golde, T. E., Schneider, L. S. & Koo, E. H. Anti-aβ therapeutics in Alzheimers disease: the need for a paradigm shift. Neuron 69, 203-213, doi: 10.1016/j.neuron.2011.01.002 (2011)
6. De Strooper, B. Lessons from a failed γ -secretase Alzheimer trial. Cell 159, 721-726, doi: 10.1016/j.cell.2014.10.016 (2014)
7. Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimers disease. N Engl J Med 367, 795-804, doi: 10.1056/NEJMoa1202753 (2012)
8. Pimplikar, S. W., Nixon, R. A., Robakis, N. K., Shen, J. & Tsai, L. H. Amyloid-independent mechanisms in Alzheimers disease pathogenesis. J Neurosci 30, 14946-14954, doi: 10.1523/jneurosci.4305-10.2010 (2010)
9. Tagawa, K. et al. Comprehensive phosphoproteome analysis unravels the core signaling network that initiates the earliest synapse pathology in preclinical Alzheimers disease brain. Hum Mol Genet 24, 540-558, doi: 10.1093/hmg/ddu475 (2015)
10. Hartwig, J. H. et al. MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-calmodulin. Nature 356, 618-622, doi: 10.1038/356618a0 (1992)
11. Agresti, A. & Bianchi, M. E. HMGB proteins and gene expression. Curr Opin Genet Dev 13, 170-178 (2003)
12. Travers, A. A. Priming the nucleosome: a role for HMGB proteins? EMBO Rep 4, 131-136, doi: 10.1038/sj.embor.embor741 (2003)
13. Qi, M. L. et al. Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases. Nat Cell Biol 9, 402-414, doi: 10.1038/ncb1553 (2007)
14. Tang, D. et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 190, 881-892, doi: 10.1083/jcb.200911078 (2010)
15. Lotze, M. T. & Tracey, K. J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5, 331-342, doi: 10.1038/nri1594 (2005)
16. Takeda, K. & Akira, S. TLR signaling pathways. Semin Immunol 16, 3-9 (2004)
17. Oakley, H. et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimers disease mutations: potential factors in amyloid plaque formation. J Neurosci 26, 10129-10140, doi: 10.1523/ jneurosci.1202-06.2006 (2006)
18. George, D. J. & Blackshear, P. J. Membrane association of the myristoylated alanine-rich C kinase substrate (MARCKS) protein appears to involve myristate-dependent binding in the absence of a myristoyl protein receptor. J Biol Chem 267, 24879-24885 (1992)
19. Taniguchi, H. & Manenti, S. Interaction of myristoylated alanine-rich protein kinase C substrate (MARCKS) with membrane phospholipids. J Biol Chem 268, 9960-9963 (1993)
20. Kim, J., Shishido, T., Jiang, X., Aderem, A. & McLaughlin, S. Phosphorylation, high ionic strength, and calmodulin reverse the binding of MARCKS to phospholipid vesicles. J Biol Chem 269, 28214-28219 (1994)
21. Calabrese, B. & Halpain, S. Essential role for the PKC target MARCKS in maintaining dendritic spine morphology. Neuron 48, 77-90, doi: 10.1016/j.neuron.2005.08.027 (2005)
22. Saito, T. et al. Single App knock-in mouse models of Alzheimers disease. Nat Neurosci 17, 661-663, doi: 10.1038/nn.3697 (2014)
23. Hama, H. et al. ScaleS: an optical clearing palette for biological imaging. Nat Neurosci 18, 1518-1529, doi: 10.1038/nn.4107 (2015)
24. Nakai, M. et al. Amyloid beta protein activates PKC-delta and induces translocation of myristoylated alanine-rich C kinase substrate (MARCKS) in microglia. Neurochem Int 38, 593-600 (2001)
25. Hasegawa, H. et al. Microglial signaling by amyloid beta protein through mitogen-activated protein kinase mediating phosphorylation of MARCKS. Neuroreport 12, 2567-2571 (2001)
26. Knowles, R. B. et al. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimers disease. Proc Natl Acad Sci USA 96, 5274-5279 (1999)
27. Holtzman, D. M. et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimers disease. Proc Natl Acad Sci USA 97, 2892-2897, doi: 10.1073/pnas.050004797 (2000)
28. Koffie, R. M. et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 106, 4012-4017, doi: 10.1073/pnas.0811698106 (2009)
29. LaFerla, F. M., Green, K. N. & Oddo, S. Intracellular amyloid-beta in Alzheimers disease. Nat Rev Neurosci 8, 499-509, doi: 10.1038/ nrn2168 (2007)
30. Friedrich, R. P. et al. Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicity. Proc Natl Acad Sci USA 107, 1942-1947, doi: 10.1073/pnas.0904532106 (2010)
31. Chen, X., Kondo, K., Motoki, K., Homma, H. & Okazawa, H. Fasting activates macroautophagy in neurons of Alzheimers disease mouse model but is insufficient to degrade amyloid-beta. Sci Rep 5, 12115, doi: 10.1038/srep12115 (2015)
32. DeKosky, S. T. & Scheff, S. W. Synapse loss in frontal cortex biopsies in Alzheimers disease: correlation with cognitive severity. Ann Neurol 27, 457-464, doi: 10.1002/ana.410270502 (1990)
33. Terry, R. D. et al. Physical basis of cognitive alterations in Alzheimers disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580, doi: 10.1002/ana.410300410 (1991)
34. Shankar, G. M. et al. Amyloid-beta protein dimers isolated directly from Alzheimers brains impair synaptic plasticity and memory. Nat Med 14, 837-842, doi: 10.1038/nm1782 (2008)
35. Banerjee, A. & Gerondakis, S. Coordinating TLR-activated signaling pathways in cells of the immune system. Immunol Cell Biol 85, 420-424, doi: 10.1038/sj.icb.7100098 (2007)
36. Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11, 373-384, doi: 10.1038/ni.1863 (2010)
37. Morrison, D. K. MAP kinase pathways. Cold Spring Harb Perspect Biol 4, doi: 10.1101/cshperspect.a011254 (2012)
38. Yang, H. et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 107, 11942-11947, doi: 10.1073/pnas.1003893107 (2010)
39. Piccinini, A. M. & Midwood, K. S. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010, 672395, doi: 10.1155/2010/672395 (2010)
40. Mills, K. H. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol 11, 807-822, doi: 10.1038/nri3095 (2011)
41. Lacor, P. N. et al. Synaptic targeting by Alzheimers-related amyloid beta oligomers. J Neurosci 24, 10191-10200, doi: 10.1523/ jneurosci.3432-04.2004 (2004)
42. Li, S. et al. Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 31, 6627-6638, doi: 10.1523/jneurosci.0203-11.2011 (2011)
43. Cissé, M. et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469, 47-52, doi: 10.1038/ nature09635 (2011)
44. Kim, T. et al. Human LilrB2 is a β -amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimers model. Science 341, 1399-1404, doi: 10.1126/science.1242077 (2013)
45. Um, J. W. et al. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 15, 1227-1235, doi: 10.1038/nn.3178 (2012)
46. Tang, S. C. et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA 104, 13798-13803, doi: 10.1073/pnas.0702553104 (2007)
47. Tahara, K. et al. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 129, 3006-3019, doi: 10.1093/brain/awl249 (2006)
48. Scaffidi, P., Misteli, T. & Bianchi, M. E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195, doi: 10.1038/nature00858 (2002)
49. Greicius, M. D., Srivastava, G., Reiss, A. L. & Menon, V. Default-mode network activity distinguishes Alzheimers disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 101, 4637-4642, doi: 10.1073/pnas.0308627101 (2004)
50. Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimers amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112, doi: 10.1038/nrm2101 (2007)
51. Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95, 6448-6453 (1998)
52. Takata, K. et al. Role of high mobility group protein-1 (HMG1) in amyloid-beta homeostasis. Biochem Biophys Res Commun 301, 699-703 (2003)
53. Takata, K. et al. Microglial Amyloid-β 1-40 Phagocytosis Dysfunction Is Caused by High-Mobility Group Box Protein-1: Implications for the Pathological Progression of Alzheimers Disease. Int J Alzheimers Dis 2012, 685739, doi: 10.1155/2012/685739 (2012)
54. Hortschansky, P., Schroeckh, V., Christopeit, T., Zandomeneghi, G. & Fändrich, M. The aggregation kinetics of Alzheimers betaamyloid peptide is controlled by stochastic nucleation. Protein Sci 14, 1753-1759, doi: 10.1110/ps.041266605 (2005)
55. Guan, Y. et al. Real-Time Monitoring of Alzheimers-Related Amyloid Aggregation via Probe Enhancement-Fluorescence Correlation Spectroscopy. ACS Chem Neurosci 6, 1503-1508, doi: 10.1021/acschemneuro.5b00176 (2015)
56. Schenk, D. et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177, doi: 10.1038/22124 (1999)
57. Bard, F. et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916-919, doi: 10.1038/78682 (2000)
58. Shilov, I. V. et al. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics 6, 1638-1655, doi: 10.1074/mcp.T600050-MCP200 (2007)
59. Klein, W. L. Abeta toxicity in Alzheimers disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41, 345-352 (2002)
60. Schagger, H. Tricine-SDS-PAGE. Nat Protoc 1, 16-22, doi: 10.1038/nprot.2006.4 (2006)
61. Nakajima, K. et al. Neurotrophins regulate the function of cultured microglia. Glia 24, 272-289 (1998)